Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Pituitary Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Carcinoma, Medullary 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1

Interventions

Cyclophosphamide 216Methotrexate 140Cytarabine 131Vincristine 110fludarabine phosphate 103Peripheral Blood Stem Cell Transplantation 98Filgrastim 92Etoposide 92Dexamethasone 89Mycophenolic Acid 71Doxorubicin 70Whole-Body Irradiation 67Mercaptopurine 66Busulfan 65Tacrolimus 64Radiotherapy 63Cyclosporine 62Prednisone 55Daunorubicin 53pegaspargase 51Asparaginase 51Rituximab 48fludarabine 47Granulocyte Colony-Stimulating Factor 46Melphalan 45Antilymphocyte Serum 43Clofarabine 42Calcium Dobesilate 38Methylprednisolone 36Leucovorin 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × pasireotide × Clear all
NCT02215070 2021-11-17

Pasireotide in Prevention of GI Toxicity

Duke University

Phase 2 Completed
37 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡